Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chubb
AstraZeneca
Accenture
Chinese Patent Office
Boehringer Ingelheim

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,130,589

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,130,589 protect, and when does it expire?

Patent 10,130,589 protects NEUPRO and is included in one NDA.

This patent has thirty patent family members in twenty-two countries.

Summary for Patent: 10,130,589
Title:Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Inventor(s): Wolff; Hans-Michael (Monheim, DE), Arth; Christoph (Monheim, DE), Quere; Luc (Braine-l'Alleud, BE), Muller; Walter (Andernach, DE)
Assignee: UCB Pharma GmbH (Monheim, DE) LTS Lohmann Therapie-Systeme AG (Andernach, DE)
Application Number:15/884,587
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,130,589
Patent Claim Types:
see list of patent claims
Use; Composition; Process;

Drugs Protected by US Patent 10,130,589

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Johnson and Johnson
Colorcon
Merck
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.